Connect with us

Market

INVESTOR ALERT: December’s Trending Biotech Stocks; VBI Vaccines Inc (VBIV), KaloBios Pharmaceuticals Inc (KBIO), Anavex Life Sciences Corp. (AVXL)

Published

on

Biotechnology stocks have had their fair share of bumps and bruises after heavy concern surrounding pricing was brought up by several presidential candidates during the first round of debates. However, since then many stocks in this sector have taken a sharp turn in favor of the bulls. In fact, several have seen news releases on new management and even merger deals spark increased attention not only on the companies but also on the industry as a whole. Companies like VBI Vaccines Inc (NASDAQ:VBIV), KaloBios Pharmaceuticals Inc (NASDAQ:KBIO), Anavex Life Sciences Corp. (NASDAQ:AVXL).

VBI Vaccines Inc (NASDAQ:VBIV) is presenting at the LD Micro Conference this week with President and CEO Jeff Baxter as the presenter. Over the more recent weeks of the last 2 months the company has undergone several key changes including a planned merger with SCIVAC THERAPEUTICS INC (OTCMKTS:SVACF). “We believe that our proposed merger with SciVac would bring a commercial vaccine together with unique vaccine development and manufacturing capabilities. We look forward to potentially combining SciVac’s assets and talent to create what we believe will become a leading global vaccine developer,” stated Baxter in a recent corporate announcement.

This planned merger also brings to the table some of the biotech industry’s notable veteran investors including Dr. Phillip Frost. This is from being SciVac’s majority shareholder, at 25% (14% post-merger) through Opko Health Inc. (NYSE:OPK). Furthermore, since hitting lows in October of $2.25, shares of VBI have rebounded by as much as 27% with volume becoming increasingly more consistent over recent weeks.

Two Biotechnology Juggernauts Are Changing The Biotech Landscape RIGHT NOW.  See Who, CLICK HERE

Amidst much excitement in the market, KaloBios Pharmaceuticals Inc (NASDAQ:KBIO) has been the source both pain and pleasure depending on how the stock was traded during the incredible run it had beginning in November of this year. What began on November 16th was one of the largest stock runs of 2015 based on overall dollar volume and price movement. Following an opening price of $0.442 on the 16th, shares of KaloBios ran to highs of $45.82 days later. This 10,266.5% move caught many traders short as Martin Shkreli acquired 70% of the outstanding shares of the company and subsequently became its CEO.

Shkreli, as well as other investors committed to an equity investment of “at least $3million apart from a $10 million equity financing facility, subject to shareholder approval,” as cited by Zacks Equity Research.

Anavex Life Sciences Corp. (NASDAQ:AVXL) announced earlier this week that it has appointed Ulrigh Elben, PhD as VP of Preclinical Operations to oversee pipeline development and optimization. Earlier in November the company reported positive results from an Alzheimer’s study. The company announced the publication of further data for Anavex 3-71 in the peer reviewed scientific journal Neurodegenerative Diseases. Evidence provided a positive and more “upstream” effect on reducing synaptic loss, amyloid and tau pathologies and neuroinflammation.

Anavex 3-71 is part of Anavex’s pipeline that also includes Anavex 2-73, which targets sigma-1 and muscarinic receptors. Since hitting lows of $3.16 in mid-November, the stock has seen a rebound of more than 150% after hitting highs of $8.16 on November 30th. The stock currently has held a price between $5.57-$7.08 since hitting those highs.

About Biotech Stocks (www.BiotechStocks.com)
Biotech Stocks (www.biotechstocks.com) is your best resource for today’s emerging biotech industry. Whether you’re looking for the best biotech stocks to buy, biotech news, trends in biotech, articles within the biotech industry and so much more, BiotechStocks.com is your destination for it all. Our goal is to become the central hub for all who are seeking current Biotech Stock News as well as biotech industry, political and social news, articles, trends & overall insight, delivered in a way that we all can relate to.

Legal Disclaimer

Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. BiotechStocks.com, is not registered with any fvb inancial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. BiotechStocks.com, may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. BiotechStocks.com, may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two. MAPH Enterprises LLC BiotechStocks.com | was paid an advertising fee of $30,000 cash & ZERO shares by the issuer for visual sponsorship on BiotechStocks.com and for visual placement of VBIV. within written materials. FOR A DURATION OF 30 DAYS BEGINNING 11/30/2015 – 1/1/2016.

Contact Info:
Email:info@biotechstocks.com
URL: www.BiotechStocks.com
SOURCE: BioTechStocks.com

Biotech

CytoDyn Inc (OTCMKTS:CYDY) Regains Momentum After The Big Announcement

Published

on

By

Now that the market seems to be coming back into his elements, it could be time for investors to start looking into penny stocks more closely. These stocks may often be risky, but if one makes the right choice, then the rewards could be enormous. One penny stock that could be put into the watch list at this point in time is that of CytoDyn Inc (OTCMKTS:CYDY).

The late-stage biotechnology company, which is developing the coronavirus medicine leronlimab, announced last week that it had filed a comprehensive application for uplisting on NASDAQ. The company announced that it believes that its application satisfies the myriad listing requirements of the NASDAQ Capital Market.

The Chief Executive Officer and President of the company Nader Pourhassan stated that while it is true that the entire process is expected to take many weeks, CytoDyn is hopeful of success in this matter.

He went on to state that a listing on NASDAQ will not only provide shareholders with more liquidity but also give CytoDyn much bigger access to fresh capital. It is a significant development for the company, and the market participants realized it as well. After the announcement was made, the stock rallied by as much as 50%. Investors could do well to keep an eye on the stock this week.

While the rally following this announcement was a welcome relief for the company, it is important to point out that earlier on in the week, the stock has fallen considerably following a setback. Last Monday, the company announced that the United States Food and Drug Administration handed CytoDyn a refusal to file a letter with regards to the usage of leronlimab to treat HIV.

However, at the same time, investors should be noted that the company did announce that it is confident of furnishing the agency with all the further details that have been demanded. It is one of the penny stocks that have performed remarkably well this year so far, and investors could keep an eye on it.

Continue Reading

Market

These 3 Pot Stocks Are Up Big Since May: What’s the Buzz?

Published

on

By

Over the course of the past year or so, pot stocks had generally struggled, but during the past month, those stocks have recovered nicely. The stock market suffered a historic fall due to the economic turmoil caused by the coronavirus pandemic. It is believed that investors who are looking for value have descended on the beaten-down pot stocks. On the flip side, these stocks could also have been identified as defensive plays in an uncertain market environment.

That being said, it should be noted that despite the gains recorded by many stocks, most of those stocks are still considerably lower than the all-time highs. In such a situation, it could be worthwhile for investors to take a closer look at some of the strongest and more stable cannabis companies in the industry. Here is a look at three pot stocks that made significant moves in May and could be tracked by investors at this point.

1. HEXO Stock Jumps Ahead of Earnings

HEXO Corp (TSX:HEXO) (NYSE:HEXO) is one of those cannabis companies which have had a particularly tough time over the past year or so. However, the stock has emerged as one of the bigger gainers among pot stocks in recent trading sessions. The Hexo stock has gained as much as 120% over the course of the past month. The company is all set to release its financial results for the fiscal third quarter on Thursday, and hence, it could be a big week for the stock.

The recent surge in the Hexo stock may have come as a major boost to investors, but it should be noted that over the past year, it recorded considerable losses. The beaten-down nature of the stock may have contributed to the stock becoming more attractive for investors. However, the trajectory of the Hexo stock in the near term is going to depend a lot on its third-quarter earnings.

The company had made a loss of $298 million in the previous quarter, and while it is almost certain that it is going to make a loss again, the size of the loss is going to be keenly watched. Additionally, any writedowns are also going to be harmful to the stock. Investors should also keep an eye on sales growth.

2 Organigram gains Momentum on Value Buying

Organigram Holdings (TSX:OGI) (NASDAQ:OGI) is another pot stock that has made significant gains in the past month. Since May 13, the stock has gained as much as 80%. In April, the company announced its fiscal second-quarter results, but it had been a disappointment.

Revenues dropped by 13.7% year on year to hit CA$23.2 million, and losses widened to CA$6.8 million from CA$6.4 million in the prior-year period. However, one significant cause for optimism for Organigram investors is the fact that in the second quarter, cannabis 2.0 products made up as much as 13% of its revenue. That has opened up a whole new opportunity for the company.

Wholesale cannabis revenue made up 24% of the net, and that is again a new source of revenue. The company blamed the lower volumes of flower as well as cannabis oil for the drop in sales. Organigram reported cash and cash equivalents of CA$41.1 million as of February 29. Considering the fact that it has burned CA$25 million in the past six months, investors should not use that the cash balance does not paint a pretty picture.

3 Aphria Recovers Following Solid Earnings

Aphria (TSX:APHA) (NYSE:APHA), on the other hand, managed to perform relatively well in its fiscal third quarter. The net sales rose by as much as 19.7% sequentially to hit CA$144.4 million, and more importantly, the company also managed to record a profit for the third time in four quarters. On top of that, it should be noted that although the Canadian cannabis company spends CA$124.4 million on its operations in the nine months trailing that quarter, it still reported a cash balance of CA$515 million.

The performance seems to have buoyed market participants as well, and the stock has rallied by as much as 75% since the middle of May. One of the most important things that investors are going to be looking into is whether Aphria is going to be able to maintain its profitability.

However, due to the turmoil caused by the coronavirus pandemic, it might prove difficult. That being said, it should be noted that the pandemic is going to have an equally damaging effect across the sector.

Continue Reading

Market

ConforMIS Inc (NASDAQ: CFMS): Premium Members Made A Quick 65% Profit In Just 1 week

Published

on

Well, as we know there are two types of person in the stock market one is trader and another is investor. Investors tend to put money for longer time, while traders make short term bets. We know, its not at all easy to make money in the short term especially in the equity markets. However, premium members at Traders Insights are making awesome money on our calls on our swing trading calls. WE ARE OFFERING A SPECIAL 7-Day Trial Period at Just $5 (so that everybody can make money with us and join us if satisfied). Register Here http://tradersinsights.com/pricing/
JOIN US NOW: For Details Contact us at info@tradersinsights.com

Or You can send me a friend request on facebook here https://www.facebook.com/sebastian.gomestradersinsights

Now let me show you how we made quick 43% in just 1-week which was posted to our premium members:-

We told our members in facebook private group to buy ConforMIS Inc (NASDAQ: CFMS) yesterday (march 13th) at $1.36. Now look at the price of the stock – its up 65% at $2.25 from our buy price. This is how easy money they made. If you had invested $5,000 in CFMS, it could had been moved up to $8,250. It’s not yet late, join us at info@tradersinsights.com

Continue Reading
Advertisement

Trending